Repositioning Candidate Details
| Candidate ID: | R1010 |
| Source ID: | DB06429 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Talnetant |
| Synonyms: | Talnetant |
| Molecular Formula: | C25H22N2O2 |
| SMILES: | CCC(NC(=O)C1=C(O)C(=NC2=CC=CC=C12)C1=CC=CC=C1)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment of schizophrenia. |
| CAS Number: | 174636-32-9 |
| Molecular Weight: | 382.4544 |
| DrugBank Indication: | Investigated for use/treatment in schizophrenia and schizoaffective disorders, irritable bowel syndrome (IBS), and chronic obstructive pulmonary disease (COPD). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Neuromedin-K receptor antagonist |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|